What Is Vyndamax? Uses, Dosage, and What You Need to Know in 2026

Vyndamax (tafamidis) is a first-in-class oral medication used to treat a rare, life-threatening heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Manufactured by Pfizer and FDA-approved since May 3, 2019, it was the first and only disease-modifying treatment approved specifically for ATTR-CM at the time of its launch. This guide covers everything patients and families need to know about Vyndamax in 2026.

What Is Vyndamax Used For?

Vyndamax is FDA-approved for one indication: the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Let's break down what that means:

• Wild-type ATTR-CM: Caused by aging — the transthyretin protein becomes unstable over time, even without a genetic mutation. Also called "senile systemic amyloidosis." Most common form; affects primarily men over 60.
• Hereditary ATTR-CM: Caused by a mutation in the TTR gene inherited from a parent. Over 130 TTR variants have been identified. The Val122Ile variant is more prevalent in African American patients.
• Cardiomyopathy: Disease of the heart muscle. In ATTR-CM, misfolded proteins (amyloid fibrils) deposit in the heart, causing it to stiffen and fail progressively.

Vyndamax does not cure ATTR-CM. It slows disease progression, reducing the risk of death and hospitalization from heart failure. Early initiation of therapy (NYHA Class I or II) produces the most benefit.

How Is Vyndamax Different from Vyndaqel?

Vyndamax and Vyndaqel are both made by Pfizer and contain tafamidis as the active ingredient. The key differences:

• Vyndamax: Contains tafamidis (free acid form). One 61-mg reddish-brown capsule once daily.
• Vyndaqel: Contains tafamidis meglumine (salt form). Four 20-mg capsules once daily. Being discontinued after 2025.

Vyndamax 61 mg is bioequivalent to Vyndaqel 80 mg (four capsules). They are NOT substitutable on a per-milligram basis, but the two can be clinically interchanged (i.e., your doctor can switch you from Vyndaqel 80 mg to Vyndamax 61 mg without changing your treatment).

What Is the Correct Vyndamax Dosage?

The FDA-approved dose of Vyndamax is:

• 61 mg (one capsule) orally once daily — with or without food
• Swallow whole — do not crush or cut the capsule
• Take at approximately the same time each day
• If a dose is missed, take it as soon as remembered — unless it's almost time for the next dose; then skip it. Do not double doses.
• Store at room temperature (68°F–77°F / 20°C–25°C)

No dosage adjustment is needed for elderly patients (the ATTR-ACT trial had a median patient age of 75). Moderate liver impairment may reduce drug exposure; discuss with your cardiologist.

Is Vyndamax a Controlled Substance?

No. Vyndamax is not a controlled substance. It has no DEA scheduling and no restrictions on how many prescriptions a doctor can write or refill. It requires a valid prescription but has no special DEA oversight.

What Did the Clinical Trial Show?

The approval was based on the ATTR-ACT study (published NEJM 2018). In this 30-month, placebo-controlled trial of 441 ATTR-CM patients:

• Vyndamax (tafamidis 80 mg equivalent) reduced all-cause mortality by 30%
• Cardiovascular hospitalizations were significantly reduced vs. placebo
• Quality of life and functional capacity (6-minute walk test) declined more slowly in treated patients
• Benefits were greatest in patients with NYHA Class I or II (less advanced disease)

How to Get Vyndamax

Vyndamax is only available through specialty pharmacies and requires a prescription from a cardiologist, along with insurance prior authorization. For a step-by-step guide to getting it filled, see how to find Vyndamax in stock near you. medfinder can also help identify which pharmacies near you can fill the prescription.